Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Liabilities and Shareholders Equity (2017 - 2025)

Serina Therapeutics' Liabilities and Shareholders Equity history spans 9 years, with the latest figure at $12.4 million for Q3 2025.

  • For Q3 2025, Liabilities and Shareholders Equity changed N/A year-over-year to $12.4 million; the TTM value through Sep 2025 reached $19.1 million, down 37.32%, while the annual FY2024 figure was $6.7 million, 25.02% down from the prior year.
  • Liabilities and Shareholders Equity for Q3 2025 was $12.4 million at Serina Therapeutics, up from $6.7 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $12.5 million in Q1 2023 and bottomed at $2.0 million in Q3 2022.
  • The 5-year median for Liabilities and Shareholders Equity is $5.0 million (2022), against an average of $6.8 million.
  • The largest annual shift saw Liabilities and Shareholders Equity plummeted 46.58% in 2021 before it soared 508.07% in 2023.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $3.2 million in 2021, then grew by 2.76% to $3.2 million in 2022, then soared by 176.7% to $9.0 million in 2023, then decreased by 25.02% to $6.7 million in 2024, then surged by 84.61% to $12.4 million in 2025.
  • Per Business Quant, the three most recent readings for SER's Liabilities and Shareholders Equity are $12.4 million (Q3 2025), $6.7 million (Q4 2024), and $10.7 million (Q2 2024).